
๐ช๐ต๐ฎ๐ย ๐ถ๐ย ๐๐ป๐๐ถ๐ด๐ฒ๐ปย ๐ฃ๐ฟ๐ฒ๐๐ฒ๐ป๐๐ฎ๐๐ถ๐ผ๐ปย &ย ๐๐ผ๐ย ๐๐ย ๐ช๐ผ๐ฟ๐ธ๐ย
Antigen-presenting cells (APCs) such as dendritic cells (DCs), macrophages, and B cells engulf and obtain antigens (proteins, fragments) from pathogens, dead cells, or tumors. Antigens are then processed into peptide fragments. Peptides are loaded onto Major Histocompatibility Complex (MHC) class I or class II molecules, which then travel to the cell surface ยดpresentingยด to CD8+ (MHC I) or CD4+ (MHC II) T cells [1].ย
Cross-presentation, DCsย birngย antigen fromย extraacellularย sources to MHC class I – anti viral/anti-tumor responses [2].ย
๐๐ป๐ฎ๐น๐ผ๐ด๐ย
Think of antigen presentation likeย ๐ขย ๐ฎ๐ถ๐ด๐ฆ๐ถ๐ฎย ๐ฅ๐ช๐ด๐ฑ๐ญ๐ข๐บ:ย
The APC = curatorย
The antigen (peptide) = artifact fragmentย
The MHC molecule = the display caseย
The T cell = museum visitor whose recognition (and reaction) depends on how well the fragment fits in the display case and how it’s labeledย โฏย
If the artifact is shiny (high affinity), presented clearly โ the visitor notices; ifย it’sย hidden, the visitor may miss it.ย
โฏ๐๐ฒ๐ฟ๐บ๐ฎ๐ปย ๐ฅ๐ฒ๐๐ฒ๐ฎ๐ฟ๐ฐ๐ต๐ฒ๐ฟ๐ย &ย ๐๐ผ๐ป๐๐ฟ๐ถ๐ฏ๐๐๐ถ๐ผ๐ป๐ย
Christian Kurts (University of Bonn) has done crucial work on cross-presentation, especially in self-antigen presentation and tolerance: e.g., how DCs present self-antigens via MHC I in non-infectious contexts, and how this shapes immune tolerance and autoimmunity. [3]ย
Hans-Georgย Rammenseeย (Tรผbingen) has contributed to MHC biology including rules deciding which peptides are presented, immunopeptidome studies, and applications in cancer immunotherapy.ย [4]ย โฏย
๐๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐นย ๐ฅ๐ฒ๐น๐ฒ๐๐ฎ๐ป๐ฐ๐ฒ:ย ๐๐ป๐๐ถ๐ด๐ฒ๐ปย ๐ฃ๐ฟ๐ฒ๐๐ฒ๐ป๐๐ฎ๐๐ถ๐ผ๐ปย ๐ฎ๐ป๐ฑย ๐๐๐ฅ-๐งย /ย ๐๐บ๐บ๐๐ป๐ผ๐๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ย
Although the CAR-T cells do not rely directly on classical antigen presentation for their target antigen (they have their own chimeric receptor), the antigen presentation machinery of the tumor and surrounding host cells is still critical: to prime helper CD4+ T cells, to regulate anti-tumor immunity, and for epitope spreading.ย
๐ข๐ฝ๐ฒ๐ปย ๐ค๐๐ฒ๐๐๐ถ๐ผ๐ปย
If different people have variation in how efficiently APCs edit and load peptides (due to genetic, epigenetic, or environmental differences), could we one day predict someone’s antigen presentation ยดsignatureยด and tailor vaccines [5] or immunotherapies accordingly?ย
Stay tuned for ๐๐ฎ๐ ๐ณ: ๐๐บ๐บ๐๐ป๐ผ๐น๐ผ๐ด๐ถ๐ฐ๐ฎ๐น ๐บ๐ฒ๐บ๐ผ๐ฟ๐ ๐ฎ๐ป๐ฑ ๐ถ๐บ๐บ๐๐ป๐ฒ ๐๐๐ป๐ฎ๐ฝ๐๐ฒ
๐ฅ๐ฒ๐ณ๐ฒ๐ฟ๐ฒ๐ป๐ฐ๐ฒ๐ย โฏ
1. DOI: 10.1038/nri3084ย
โฏ2. DOI: 10.3389/fimmu.2018.01643ย
3. doi.org/10.1038/nri2780ย
4. DOI: 10.1038/s41467-023-42692-7ย
5.ย doi/10.1128/msphere.00502-24ย
#100DaysOfImmunology #AntigenPresentation #MHC #CrossPresentation #Immunotherapy #CART #MechanisticBiology #ScienceEducation #Research #Immunopeptidome #Tolerance #Autoimmunity